NBIO News and Press, Nascent Biotech From 04/09/20

NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nascent Biotech, Inc. (OTCQB: NBIO) (the "Company"), a biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer, was recently featured in an article by...

SAN DIEGO, CA / ACCESSWIRE / April 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) , today announced that two independent consultants retained by the Company have begun preliminary research on a possible treatment for patients infected with the Coronavirus. An article in The Journal of Biologica...

SAN DIEGO, CA / ACCESSWIRE / March 19, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) , today announced it has begun research on a possible treatment for patients infected with COVID-19. As previously mentioned in the scientific literature ( Yu et al. Journal of Biomedical Science (2016) 23:14 DOI...

San Diego, CA, Feb. 05, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) is pleased to release a recent interview with company President | CEO Sean Carrick, on The Wall Street Analyzer, a multi-media financial research and publishing compa...

SAN DIEGO, CA , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will be presenting on “Navigating the Unique Challenges Presented in Immune Oncology trials” in San Diego on February 12th. The meeting wi...

San Diego, CA, Jan. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), an emerging biotech company, with IND Clearance and IRB approval to begin Clinical trials for Brain Cancer, is very pleased to announce that Marble Arch Research Inc., a leading indepen...

SAN DIEGO, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB:NBIO), a biopharmaceutical company focusing on the development of monoclonal antibodies for the treatment of various types of cancers, announces an agreement with TRITON FUNDS LP. TRI...

Study Planned for Multiple Brain Cancer Types in Phase I Setting San Diego, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced they have entered into a contractual agreement in Orange County, CA to conduct Phase I human clini...

San Diego, CA, June 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTC: NBIO) announced today that two of its Senior Officers have converted the Company’s liability to them to common stock. Nascent Executive Vice President of Business Development Brandon P...

SAN DIEGO, CA, May 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will present an abstract on a natural human lgG1 mAb, Pritumumab, which targets cell surface expressed vimentin and inhibits tumor growth, at the AAI convention...